Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Adams

Urology Charleston, SC Medical Doctor

NPI 1013081678 CMS profile 272674

171 Ashley Ave, Charleston, SC 29425

Open in the dashboard

General payments

$14,686

154 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Adams of Charleston, SC is reported in the CMS Open Payments database as having received $14,686 across 154 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $423 10
2024 General $706 10
2023 General $1,426 14
2022 General $2,574 31
2021 General $2,788 29
2020 General $3,023 25
2019 General $3,745 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Adams
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to John Adams were reported at $423. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year John Adams Urology median Middle half National median
2019 $3,745 $480 $147–$1,201 $163
2020 $3,023 $246 $87–$645 $114
2021 $2,788 $358 $111–$1,000 $132
2022 $2,574 $476 $143–$1,263 $149
2023 $1,426 $560 $168–$1,461 $160
2024 $706 $563 $170–$1,464 $164
2025 $423 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $10,832 37 payments
  2. PROCEPT BioRobotics Corporation $1,191 7 payments
  3. Arthrex, Inc. $323 2 payments
  4. Teleflex LLC $318 10 payments
  5. Olympus America Inc. $228 6 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $181 13 payments
  7. Calyxo, Inc. $144 1 payment
  8. Astellas Pharma US Inc $124 8 payments
  9. Allergan Inc. $115 8 payments
  10. Coloplast Corp $99 5 payments
  11. Other $1,129 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $10,462 30 payments
  2. Food and Beverage $3,400 119 payments
  3. Travel and Lodging $800 4 payments
  4. Education $24 1 payment
Products named General payments · program years 2019–2025
  1. General - Therapies $4,367 12 payments
  2. GENERAL THERAPIES $2,439 8 payments
  3. AMPLATZ $1,673 4 payments
  4. PERCUFLEX $1,579 4 payments
  5. AQUABEAM ROBOTIC SYSTEM $804 4 payments
  6. Clear Renal Sheath $403 2 payments
  7. AQUABEAM SYSTEM $387 3 payments
  8. UROLIFT $265 6 payments
  9. iTIND System $228 6 payments
  10. JARDIANCE $181 13 payments
  11. Other $1,974 91 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

760

Median for Urology: 1,053

Drug cost

$68,186

Median for Urology: $101,464

Branded share of claims

18.2%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 52 $38,900
Gemtesa Vibegron Brand 22 $11,109
Tamsulosin Hcl Generic 286 $3,988
Methenamine Hippurate Generic 50 $3,875
Tadalafil Generic 61 $3,488
Estradiol Generic 28 $2,126
Solifenacin Succinate Generic 40 $1,674
Finasteride Generic 54 $681
Oxybutynin Chloride Er Oxybutynin Chloride Brand 14 $611
Dutasteride Generic 12 $558

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$107,076

Medicare's payments for the services billed

Medicare patients

431

Average age 73

Services billed

1,676

90 women, 341 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 34%
Chronic kidney disease 33%
Cancer 30%
Ischemic heart disease 28%
Atrial fibrillation 23%
Depression 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

154 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record